Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Summary

The purpose of this study is to identify predictive molecular markers of response to continuous daily sunitinib at dose of 37.5 mg used in patients with poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors. Hypothesis: * To distinguish molecular markers based on their expression at the initial biopsy, their detection by proteomic analysis and demonstrating that tumor or vascular cells are straightaway sensitive to sunitinib (markers sensitivity). * The presence of these markers at the initial biopsy predict the sensitivity to sunitinib(Positive predictive value of markers)

Timeline

Start

2008-10

Primary completion

2013-12

Completion

2014-12

Outcome

Outcome not reported

Stopped (Enrollment): “lack of recruitement”

Drugs

Indications